✦ LIBER ✦

Dissecting racial disparities in the treatment of patients with locoregional pancreatic cancer : A 2-Step Process

✍ Scribed by Taylor S. Riall; Courtney M. Townsend Jr.; Yong-Fang Kuo; Jean L. Freeman; James S. Goodwin

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 169 KB
Volume: 116
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.24836

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Racial disparities and treatment trends

Racial disparities and treatment trends in a large cohort of elderly black and white patients with nonsmall cell lung cancer

✍ Dale Hardy; Chih-Chin Liu; Rui Xia; Janice N. Cormier; Wenyaw Chan; Arica White; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 264 KB 👁 1 views

## Abstract ## BACKGROUND: This study investigated whether there was a significant gap in receipt of treatment for nonsmall cell lung cancer (NSCLC) between blacks and whites, and whether the gap or disparity changed during the past 12 years from 1991 to 2002. ## METHODS: The study population co

A trial of 1−(2−chlorethyI)−3−(4−methyl-

A trial of 1−(2−chlorethyI)−3−(4−methyl-cyclohexyl)-1-nitrosourea in the treatment of patients with advanced gastro-intestinal cancer

✍ G. R. Giles; R. Hall; T. G. Brennan; T. S. Worthy 📂 Article 📅 1974 🏛 John Wiley and Sons 🌐 English ⚖ 269 KB

Long-term results of the treatment of pa

Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group

✍ David J. Inwards; Paul A. S. Fishkin; David W. Hillman; David W. Brown; Stephen 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 1 views

## Abstract ## BACKGROUND. The objective of this study was to test cladribine (2‐CDA) alone and in combination with rituximab in patients with mantle cell lymphoma (MCL). ## METHODS. Patients with MCL were treated on 2 sequential trials. In Trial 95‐80‐53, patients received 2‐CDA as initial ther

Combination therapy with fludarabine and

Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma : A phase 2 trial of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; Elizabeth R. Vazquez; David R. Spigel; Eric Raefsky; James D 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 2 views

## Abstract ## BACKGROUND The purpose of the current study was to evaluate the efficacy and toxicity of the combination of fludarabine and rituximab, followed by alemtuzumab, as first‐line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ## METHO